Elypta is a molecular diagnostic company focused on preventing cancer mortality by developing a liquid biopsy platform for detection and monitoring of the disease.
Elypta's mission is to prevent cancer mortality through earlier detection and closer monitoring.
Elypta was founded in 2017 by Francesco Gatto and Jens Nielsen. The company is headquartered in Stockholm, Sweden, with an office in Johanneberg, Vastra Gotaland County, Sweden.
Elypta's technology is being developed to ultimately be validated across multiple cancers and address a global market. The initial application will be a urine test for early detection of recurring kidney cancer, a condition where there are no suitable tests currently available.
Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in our lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. We also explore several other indications to understand the full potential for Elypta’s platform.
Elypta is backed by Industrifonden and Sciety, Norrsken Foundation, Nina Capital, Chalmers Ventures and others. The company raised €6.1M ($6.8M) in a late Seed round on Jan 23, 2020. This brings Elypta's total funding to $12.3M to date.